A Review on Reduction in liver Stiffness Parameters by Modulating Inflammatory Mediators in Nash

NASH is an advanced form of NAFLD. NASH is a more severe form of NAFLD characterized by hepatic steatosis, inflammation, hepatocellular injury and fibrosis. NASH has emerged as the most common cause of end stage liver disease worldwide. NASH is a chronic inflammation that transforms hepatic stellate cells to myofibroblast. These cells produce extracellular matrix that can lead to liver fibrosis. Extracellular vesicle act as a signaling mediator that result in lipid accumulation, macrophage and hepatic stem cell activation that causes inflammation and liver fibrosis during development of NASH. Life style interventions are most effective and essential for preventing or controlling NASH. Pharmacological management of NASH remains elusive. Incorporation of drugs with personalized mechanism can lead to improved efficacy to better benefit patients with NASH.